100% Quality Guarantee
PhD-Level Technical Support
Key Features

GenieFluor 647 Anti-Mouse CD22 Antibody [Cy34.1] (AGEL0728)

SKU AGEL0728
Product Type Antibody
Antibody Type Monoclonal Antibody
Reactivity Mouse
Applications FC
€123 - €344

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

GenieFluor 647 Anti-Mouse CD22 Antibody [Cy34.1]

The Mouse CD22 Monoclonal Antibody (AF647 Conjugated, CY34.1) is a valuable research tool designed for the study of CD22, a cell surface protein with important implications in immune regulation and B cell function. This monoclonal antibody, conjugated with AF647 for fluorescent detection, is specially developed for use in flow cytometry and immunofluorescence applications, allowing for precise identification and analysis of CD22 expression in various cell populations.CD22 is a key regulator of B cell activation and survival, playing a crucial role in modulating immune responses and maintaining immune tolerance.

Dysregulation of CD22 has been implicated in various autoimmune diseases and B cell malignancies, making it a significant target for investigation in immunology and oncology research. This antibody provides researchers with a reliable tool for exploring the role of CD22 in different biological contexts, aiding in the advancement of knowledge on B cell biology and the development of potential therapies targeting CD22-related pathways.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose